Duke neurosurgeon Peter E. Fecci, MD, PhD, has been named associate deputy director of the Preston Robert Tisch Brain Tumor Center at Duke.
Fecci also serves as assistant professor of neurosurgery and pathology; director of the Brain Tumor Immunotherapy Program; and co-director of the Duke Center for Brain and Spine Metastasis.
He has had a highly decorated research career focusing on brain tumors and immunotherapy. His research focusing on T-cell dysfunction in patients with glioblastoma has earned him several awards and an international reputation. He received the Sontag Distinguished Scientist Award in 2015 and recently obtained an NIH R01 grant, research which has instigated an entirely new class of anti-cancer therapy.
"Peter has an emerging track record in leadership and administration of research and will be of great assistance to all of us in the brain tumor center as we build our future vision," says David Ashley, director of the Preston Robert Tisch Brain Tumor Center. "I'm very grateful to Peter for accepting this role."
Fecci completed his undergraduate training at Cornell University, graduating in the top 1% of his class, and received a full scholarship at Duke University School of Medicine. He received postgraduate training at Massachusetts General Hospital and the Dana Farber Cancer Institute and rejoined Duke in 2014.
Established in 1937, The Preston Robert Tisch Brain Tumor Center was one of the first brain tumor research and clinical programs in the United States. Since then, it has advanced to become one of the best pediatric and adult neuro-oncology programs in the world—leading the way in comprehensive care that combines research breakthroughs, clinical trials and the newest therapies. The center sees up to 800 new adult brain tumor patients each year and up to 75 new pediatric brain tumor patients each year from across the country and around the world.